HYLEUKIN-7

Dead / Abandoned — Abandoned — no statement of use filed (as of 25 Jan 2021)

What this means for you

This application is over — abandoned 25 Jan 2021. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
88469477
Mark type
Stylized text
Filed
12 Jun 2019
Published for opposition
28 Apr 2020
Abandoned
25 Jan 2021
Attorney of record
James R Menker

Goods and services

  • Class 005 — Pharmaceuticals: Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent for medical purposes, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; Vaccines; Pharmaceutical preparations for the treatment of lymphopenia; Immunoglobulin fusion protein pharmaceutical preparations, namely, antibodyfusion proteins for the treatment of cancer

Owner

Prosecution history

  • 25 Jan 2021 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
  • 25 Jan 2021 — ABANDONMENT - NO USE STATEMENT FILED
  • 23 Jun 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 28 Apr 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 28 Apr 2020 — PUBLISHED FOR OPPOSITION
  • 08 Apr 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 25 Mar 2020 — ASSIGNED TO LIE
  • 19 Mar 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 18 Mar 2020 — EXAMINER'S AMENDMENT ENTERED
  • 18 Mar 2020 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
  • 18 Mar 2020 — EXAMINERS AMENDMENT E-MAILED
  • 18 Mar 2020 — EXAMINERS AMENDMENT -WRITTEN
  • 24 Feb 2020 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 24 Feb 2020 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 24 Feb 2020 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

View this trademark record on Marksy